[{"id":"d5759c67-38af-4af9-abd7-b55f8e507820","acronym":"","url":"https://clinicaltrials.gov/study/NCT04556539","created_at":"2021-01-18T21:46:50.966Z","updated_at":"2024-07-02T16:36:30.403Z","phase":"Phase 2","brief_title":"Study of SC10914 in Patients With gBRCA1/2 Mutation Advanced Ovarian Cancer","source_id_and_acronym":"NCT04556539","lead_sponsor":"Jiangxi Qingfeng Pharmaceutical Co. Ltd.","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SC10914"],"overall_status":"Recruiting","enrollment":" Enrollment 104","initiation":"Initiation: 12/15/2020","start_date":" 12/15/2020","primary_txt":" Primary completion: 12/31/2021","primary_completion_date":" 12/31/2021","study_txt":" Completion: 12/31/2022","study_completion_date":" 12/31/2022","last_update_posted":"2021-05-12"},{"id":"c058bccd-1e8a-4b22-9255-574822d5c1a1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04556292","created_at":"2021-01-18T21:46:48.109Z","updated_at":"2024-07-02T16:36:40.880Z","phase":"Phase 2","brief_title":"A Phase II Study to Assess the Efficacy and Safety of SC10914 in the Metastatic Breast Cancer Patients","source_id_and_acronym":"NCT04556292","lead_sponsor":"Jiangxi Qingfeng Pharmaceutical Co. Ltd.","biomarkers":" BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • PGR positive","tags":["BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • SC10914"],"overall_status":"Recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 08/12/2020","start_date":" 08/12/2020","primary_txt":" Primary completion: 03/30/2022","primary_completion_date":" 03/30/2022","study_txt":" Completion: 08/30/2022","study_completion_date":" 08/30/2022","last_update_posted":"2020-09-21"},{"id":"596a8d0a-9a09-494e-93d3-b1beadfdd35e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04486937","created_at":"2021-01-18T21:32:22.465Z","updated_at":"2024-07-02T16:36:42.734Z","phase":"Phase 1/2","brief_title":"SC10914 Monotherapy for the mCRPC With g/s BRCA Mutation","source_id_and_acronym":"NCT04486937","lead_sponsor":"Jiangxi Qingfeng Pharmaceutical Co. Ltd.","biomarkers":" BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SC10914"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 08/30/2020","start_date":" 08/30/2020","primary_txt":" Primary completion: 12/30/2021","primary_completion_date":" 12/30/2021","study_txt":" Completion: 06/30/2022","study_completion_date":" 06/30/2022","last_update_posted":"2020-07-27"},{"id":"43e10b1a-f6dd-4102-b559-116081ca41ce","acronym":"","url":"https://clinicaltrials.gov/study/NCT02940132","created_at":"2021-01-17T17:55:31.388Z","updated_at":"2024-07-02T16:37:15.762Z","phase":"Phase 1","brief_title":"A Study of SC10914 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT02940132","lead_sponsor":"Jiangxi Qingfeng Pharmaceutical Co. Ltd.","biomarkers":" BRCA1 • BRCA2 • ATM","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • BRCA1 expression • ATM expression","tags":["BRCA1 • BRCA2 • ATM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • BRCA1 expression • ATM expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SC10914"],"overall_status":"Unknown status","enrollment":" Enrollment 72","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 03/01/2018","primary_completion_date":" 03/01/2018","study_txt":" Completion: 05/01/2018","study_completion_date":" 05/01/2018","last_update_posted":"2017-12-06"}]